These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 14672928)

  • 1. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
    Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
    J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    Liu B; Yu X; Luo K; Yu Y; Yu XF
    J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Sheehy AM; Gaddis NC; Malim MH
    Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function.
    Kobayashi M; Takaori-Kondo A; Miyauchi Y; Iwai K; Uchiyama T
    J Biol Chem; 2005 May; 280(19):18573-8. PubMed ID: 15781449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Yu X; Yu Y; Liu B; Luo K; Kong W; Mao P; Yu XF
    Science; 2003 Nov; 302(5647):1056-60. PubMed ID: 14564014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction between HIV-1 Gag and APOBEC3G.
    Cen S; Guo F; Niu M; Saadatmand J; Deflassieux J; Kleiman L
    J Biol Chem; 2004 Aug; 279(32):33177-84. PubMed ID: 15159405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Marin M; Rose KM; Kozak SL; Kabat D
    Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization.
    Wichroski MJ; Ichiyama K; Rana TM
    J Biol Chem; 2005 Mar; 280(9):8387-96. PubMed ID: 15537645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and host.
    Argyris EG; Pomerantz RJ
    Trends Microbiol; 2004 Apr; 12(4):145-8. PubMed ID: 15116720
    [No Abstract]   [Full Text] [Related]  

  • 12. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
    J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Conticello SG; Harris RS; Neuberger MS
    Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
    Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
    Kremer M; Schnierle BS
    Curr HIV Res; 2005 Oct; 3(4):339-44. PubMed ID: 16250885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.
    Ribeiro AC; Maia e Silva A; Santa-Marta M; Pombo A; Moniz-Pereira J; Goncalves J; Barahona I
    J Virol; 2005 Jan; 79(2):823-33. PubMed ID: 15613310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
    Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
    J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
    Goncalves J; Santa-Marta M
    Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.